Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

FAPIBODY Next-Generation FAP Tracers: Single-Domain Antibody–FAPI Conjugates for Cancer Theranostics

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 August 2026 to 31 July 2028
Status
Running
EU funding
€200k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101280567

What the project is doing

In the project's own words, from its summary on CORDIS.

This proposal aims to create next-generation molecular imaging probes for cancer by targeting the fibroblast activation protein (FAP), a prominent biomarker of cancer-associated fibroblasts. FAP small-molecule inhibitors (FAPIs) have recently shown great promise for PET imaging, enabling sensitive visualization of tumors across multiple cancer types. However, despite their clinical impact, current FAPIs suffer from rapid systemic clearance and limited tumor retention, restricting their diagnostic sensitivity and therapeutic applicability.

To address these shortcomings, this project introduces an innovative multivalent strategy that combines the potency of FAPIs with the specificity of single-domain antibodies (sdAbs). The proposal is structured around four main objectives: (1) systematic identification and characterization of sdAbs with strong affinity, high residence time, stability, and favorable biophysical properties; (2) chemical synthesis and optimization of sdAb–FAPI conjugates with tailored linkers to maximize stability and functionality; (3) structural and mechanistic validation of binding interactions using cryo-electron microscopy (cryo-EM), providing molecular-level insights for rational probe design; and (4) radiolabeling of the most promising conjugates and preclinical validation in PET/SPECT imaging to benchmark their performance against reference FAP tracers.

By combining approaches from , chemical biology, structural biology, enzymology and radiopharmacy, the proposal will deliver innovative FAP-targeted probes with enhanced tumor retention, improved imaging quality, and expanded theranostic potential. These outcomes will not only advance cancer diagnostics but may also open new opportunities for treating diseases characterized by FAP expression.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI